Arcutis Biotherapeutics, Inc. (ARQT) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0001787306 · SEC filings checked Oct 18, 2026

    Next report
    Nov 4, 2026
    Estimated from reporting history (91-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $28.82
    Polygon.io daily close, Oct 16, 2026. End of day, not live.
    Trailing diluted EPS
    $0.22
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 131.0

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 5, 2026$129.9M$15.0M$0.11Filing
    Mar 31, 2026May 6, 2026$105.4M$-11.3M$-0.09Filing
    Dec 31, 2025Feb 25, 2026$129.5M$17.4M$0.14Filing
    Sep 30, 2025Oct 28, 2025$99.2M$7.4M$0.06Filing
    Jun 30, 2025Aug 6, 2025$81.5M$-15.9M$-0.13Filing
    Mar 31, 2025May 6, 2025$65.8M$-25.1M$-0.20Filing
    Dec 31, 2024Jan 13, 2025$71.4M$-10.8M$-0.09Filing
    Sep 30, 2024Nov 6, 2024$44.8M$-41.5M$-0.33Filing

    What would Arcutis Biotherapeutics, Inc. have to report for its valuation to change?

    At $28.82, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 62.1% a year, to $2.46. On that path the next quarter needs diluted EPS near $0.10, against $0.06 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year62.1%62.1%
    EPS needed in final year$2.46$2.46

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ARQT goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.